Canaccord raised the firm’s price target on Artivion (AORT) to $41 from $35 and keeps a Buy rating on the shares. The firm said they posted a strong Q2 beat and raise driven by Aortic Stent Graft (AMDS) and On-X strength. Canaccord believes that Q2 is just the start for the company especially considering its deep pipeline of PMA products.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AORT: